CD22 and lymphoma: The press release reporting on the study termination concluded that “hematologic cancers are a complex group of diseases, with more than 70 different types of lymphomas, leukemias or myelomas that require unique treatment options.” Therefore, clinical development of anti-CD22 ADCs with alternative payloads remains of utmost importance.